Yahoo Finance Today's Research Reports on Trending Tickers: Incyte and Supernus Pharmaceuticals
NEW YORK, NY / ACCESSWIRE / December 4, 2018 / U.S. markets closed up on Monday as the U.S. and China came to an agreement of a 90-day trade war truce at the G-20 meeting in Argentina. The Dow Jones Industrial Average jumped 1.13 percent to close at 25,826.43, while the S&P 500 Index increased 1.09 percent to close at 2,790.37. The Nasdaq Composite Index hiked 1.51 percent to close at 7,441.51.
According to UBS Global Wealth Management chief investment officer, Mark Haefele, "At this time, markets view the news as modestly positive for risk assets, while President Trump described the bilateral meeting with China as 'amazing and productive,' we believe the rivalry between the US and China will not be easily overcome, especially over the issue of intellectual property and market access."
The Market Edge Initiates Coverage on:
Incyte Corporation
https://marketedgereport.com/report/INCY/
Supernus Pharmaceuticals, Inc.
https://marketedgereport.com/report/SUPN/
Incyte's stock jumped 6.33% Monday, to close the day at $68.32. The stock recorded a trading volume of 2,690,531 shares, which was above its three months average volume of 1,504,361 shares. In the last year, Incyte's shares have traded in a range of 58.33 - 102.63. The share price has gained 17.13% from its 52 week low. The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $65.19 is below its 200-day moving average of $67.70. Shares of Incyte have gained roughly 1.35 percent in the past month and are down 27.86 percent year-to-date.
Access The Market Edge's Incyte Corporation Research Report:
https://marketedgereport.com/report/INCY/
On Monday, shares of Supernus Pharmaceuticals recorded a trading volume of 647,705 shares, which was above the three months average volume of 561,558 shares. The stock ended the day 3.04% higher at $48.86. The share price has fallen 20.23% from its 52 week high with a 52 week trading range of 34.90 - 61.25. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $45.45 is below its 200-day moving average of $49.81. Shares of the company are trading at a Price to Earnings ratio of 26.74. Shares of Supernus Pharmaceuticals have gained roughly 5.05 percent in the past month and are up 22.61 percent year-to-date.
Access The Market Edge's Supernus Pharmaceuticals, Inc. ResearchReport:
https://marketedgereport.com/report/SUPN/
Our Actionable Research on Incyte Corporation (NASDAQ:INCY) and Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) can be downloaded free of charge at The Market Edge.
The Market Edge
We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.
The Market Edge has not been compensated; directly or indirectly; for producing or publishing this document.
Disclaimer: This article is written by an independent contributor of MarketEdgeReport.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. MarketEdgeReport.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.marketedgereport.com/disclaimer.
CONTACT
For any questions, inquiries, or comments reach out to us directly at:
Address:
The Market Edge, Unit #901 511 Avenue of the Americas, New York, NY, 10011
Email:
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: The Market Edge
